Yuhan Corporation announced on the 24th that it has signed a domestic supply contract with Bayer Korea for Bepanthen ointment and Canesten.
Accordingly, the two companies will conduct joint promotions for Bepanthen ointment and Canesten products starting next month. Yuhan Corporation aims to further expand its market share in domestic treatments for skin diseases and women's health, including vulvovaginal candidiasis and vulvitis, through this contract.
Bepanthen ointment is the first non-steroidal dermatitis treatment containing dexpanthenol, currently recording the highest global sales in the skin disease field. It is used to soothe sensitive skin and restore damaged skin barriers, treating various skin conditions such as diaper rash in infants, acute and chronic dermatitis, wounds, eczema, and sunburn.
Canesten is an antifungal treatment primarily composed of clotrimazole, used for superficial fungal infections and vulvovaginal candidiasis, and is available in various formulations, including cream, suppositories, and powder. Canesten is the world's best-selling treatment for candidiasis and vulvitis.
Jo Wook-je, CEO of Yuhan Corporation, noted, "Through this agreement, I hope that consumers in Korea will be able to access globally superior quality products more easily, leveraging the strengths of both companies."
Oh Young-kyung, head of the Consumer Health Division at Bayer Korea, said, "We will enhance domestic consumers' accessibility to Bayer products that can manage various common skin diseases and women's health issues more conveniently and effectively."